human pdgf-bb antibody  (Bio-Techne corporation)

Journal: Frontiers in Veterinary Science

Article Title: Evaluation of Platelet-Rich Plasma by means of PRGF ® -Endoret ® protocol in leukemia cats: PDGF-BB and TGF-ß1 valuation

doi: 10.3389/fvets.2023.1110055

Figure Lengend Snippet: Mean ± SD of platelet (PLT) concentrations, mean platelet volume (MPV), erythrocytes (RBCs), leukocytes (WBC), lymphocytes (LYMPH), neutrophils (NFS), and monocytes (MON) concentrations in whole blood (WB) samples and in the PRP and PPP fractions; platelet-derived growth factor BB (PDGF-BB) and transforming growth factor B1 (TGF-β1) concentrations in the PRP and PPP fractions in 11 FeLV cats ( n = 11).

Article Snippet: The concentrations of both GFs in both plasma fractions (PPP and PRP) were determined using an ELISA kit of development with antibodies to human (Human TGF-beta1 DuoSet ELISA de R&D Systems DY240-05 and Human PDGF-BB DuoSet ELISA de R&D Systems DY220, respectively), following the methodology previously published by Miguel-Pastor et al. ( ).

Techniques:

Journal: Frontiers in Veterinary Science

Article Title: Evaluation of Platelet-Rich Plasma by means of PRGF ® -Endoret ® protocol in leukemia cats: PDGF-BB and TGF-ß1 valuation

doi: 10.3389/fvets.2023.1110055

Figure Lengend Snippet: Comparison of Platelet-Derived Growth Factor-BB [PDGF-BB; (A) ] and transforming growth factor ß1 [TGF-ß1; (B) ] concentrations (mean ± SD) in FeLV cats ( n = 11) between PRP and PPP fractions. Different letters (a, b) indicate differences between groups. P < 0.05 statistically different.

Article Snippet: The concentrations of both GFs in both plasma fractions (PPP and PRP) were determined using an ELISA kit of development with antibodies to human (Human TGF-beta1 DuoSet ELISA de R&D Systems DY240-05 and Human PDGF-BB DuoSet ELISA de R&D Systems DY220, respectively), following the methodology previously published by Miguel-Pastor et al. ( ).

Techniques: Comparison, Derivative Assay

Journal: Genome Medicine

Article Title: A dynamic single cell-based framework for digital twins to prioritize disease genes and drug targets

doi: 10.1186/s13073-022-01048-4

Figure Lengend Snippet: Construction of MNMs and prioritization of URs. A (1) Determination of DEGs (red) in a cell type (gray). (2) Bioinformatic identification of the predicted UR of the DEGs. (3) Identification of another cell type (blue) in which that UR is differentially expressed. (4) A directed interaction from the blue to the gray cell type is formed. B Example of one MNM (at 0 h) which was constructed based on directed interactions as described in A. C MNMs created at each time point. Node sizes correspond to the number of DEGs between cells isolated from patients compared to healthy controls. Edge width represents the number of predicted URs. Edge color corresponds to the source cell. D Heatmap of top 40 URs ranked based on the number of cell types that each UR is predicted to regulate at different time points. Color intensity boxes indicate the statistical significance of predictions. Grey boxes indicate non-significant predictions. A positive z-score indicates that the direction of the differential expression matches the predicted direction (orange), while a negative z-score indicates the opposite (blue). The inserted boxes on the right correspond to the top 20 URs in the left boxes. E , F Dynamic UR-target models showing predicted cell-type targets of PDGF-BB and IL-4 in allergen-stimulated patients. Node size denotes the significance of the association (z-score)

Article Snippet: For blocking experiments, PBMCs (1 × 10 6 cells) from eight SAR patients were stimulated for 5 days with 10 μg/mL BPE in the absence or presence of either a neutralizing anti-human IL-4 antibody (MAB204) or anti-human PDGF-BB antibody (AF-220-NA, both from R&D Systems, Minneapolis, USA) at a concentration of 5 μg/mL.

Techniques: Construct, Isolation, Quantitative Proteomics

Journal: Genome Medicine

Article Title: A dynamic single cell-based framework for digital twins to prioritize disease genes and drug targets

doi: 10.1186/s13073-022-01048-4

Figure Lengend Snippet: Protein expression patterns of predicted URs in supernatants of allergen-stimulated PBMC from SAR patients and controls. A PDGF-BB, B IFN-α, and C CCL5 levels in supernatants. * P -value < 0.05, ** P -value < 0.01, Wilcoxon signed rank test

Article Snippet: For blocking experiments, PBMCs (1 × 10 6 cells) from eight SAR patients were stimulated for 5 days with 10 μg/mL BPE in the absence or presence of either a neutralizing anti-human IL-4 antibody (MAB204) or anti-human PDGF-BB antibody (AF-220-NA, both from R&D Systems, Minneapolis, USA) at a concentration of 5 μg/mL.

Techniques: Expressing

Journal: Genome Medicine

Article Title: A dynamic single cell-based framework for digital twins to prioritize disease genes and drug targets

doi: 10.1186/s13073-022-01048-4

Figure Lengend Snippet: Effects of PDGF-BB neutralization on the release of IL-6, IL-13, and VEGF from allergen-stimulated PBMC. A IL-6, B IL-13, and C VEGF levels in supernatants harvested at day 5; D allergen-specific lymphoproliferation. Box plots are shown, red lines indicate median values, * P -value < 0.05, Wilcoxon signed ranks test. The different shapes of data points represent different SAR patients

Article Snippet: For blocking experiments, PBMCs (1 × 10 6 cells) from eight SAR patients were stimulated for 5 days with 10 μg/mL BPE in the absence or presence of either a neutralizing anti-human IL-4 antibody (MAB204) or anti-human PDGF-BB antibody (AF-220-NA, both from R&D Systems, Minneapolis, USA) at a concentration of 5 μg/mL.

Techniques: Neutralization